WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference.
|Date:||Thursday, November 12, 2020|
|Time:||3:30 PM Eastern Time|
A live audio webcast and replay of the presentations will be available in the Investors section on the Company’s website at www.bellerophon.com.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
|At W2O Group:||At LifeSci Advisors:|
|Julie Normart||Brian Ritchie|
|(559) 974-3245||(212) 915-2578|
|[email protected]||[email protected]|